|
|
Article: Pathogenesis Corp. Announces First International Approvals Of TOBI(R) (Tobramycin Solution for Inhalation).
- Article from:
- PR Newswire
- Article date:
- February 16, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SEATTLE, Feb. 16 /PRNewswire/ -- PathoGenesis Corp. (Nasdaq: PGNS) today announced it has received marketing clearance from regulatory authorities in Canada and Argentina for TOBI(R) (tobramycin solution for inhalation). The drug is indicated for the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa infections.
Canada and Argentina represent the first markets for TOBI outside the U.S., where the drug was introduced in January 1998. TOBI is expected to be available for sale in Canada in the second quarter. Some 3,000 Canadians with cystic fibrosis are treated primarily at 36 cystic fibrosis specialist centers. In Argentina, ...